City

Clinical trials near Hangzhou, China

Active studies with a listed research site in Hangzhou, China.

26active studies

14recruiting now

5countries represented

138largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowNot applicable

Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity

Colonic NeoplasmsCondition

Laparoscopic surgery, Open surgeryTreatment

China1 locations

Second Affiliated Hospital, Zhejiang University, School of MedicineSponsor

Updated 2026-06-03 · NCT07314996See eligibility →

Recruiting nowNot applicable

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

Bipolar Disorder (BD)Condition

Temporal Interference Stimulation, Sham Temporal Interference Stimulation Arm DescriptionTreatment

China1 locations

First Affiliated Hospital of Zhejiang UniversitySponsor

Updated 2026-05-27 · NCT07589647See eligibility →

Recruiting nowPhase 1

A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses

Obesity, OverweightCondition

SHR-2906 Injection, SHR-2906 Injection PlaceboTreatment

China1 locations

Beijing Suncadia Pharmaceuticals Co., LtdSponsor

Updated 2026-05-14 · NCT07280936See eligibility →

Recruiting nowNot applicable

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Obesity, Weight ControlCondition

Mazdutide, Intensive Lifestyle InterventionTreatment

China13 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-04-08 · NCT07517042See eligibility →

Recruiting nowNot applicable

Probiotic Intervention on Body Weight

Obesity, HomeostasisCondition

General lifestyle and nutritional education, Energy-restricted nutritional and lifestyle interventionTreatment

China1 locations

Chinese Academy of SciencesSponsor

Updated 2026-03-17 · NCT06989177See eligibility →

Recruiting nowNot applicable

Protein Supplementation Intervention on Body Weight

Obesity, Weight LossCondition

General lifestyle and nutritional education, Calorie-restricted balanced dietTreatment

China1 locations

Chinese Academy of SciencesSponsor

Updated 2026-03-17 · NCT06989203See eligibility →

Recruiting nowNot applicable

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients

Hypoxemia, Esophageal CancerCondition

COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation, High-Flow Nasal Cannula OxygenationTreatment

China5 locations

Zhejiang UniversitySponsor

Updated 2026-03-11 · NCT07175155See eligibility →

Recruiting nowPhase 1

Bioequivalence Study of BGM0504 Injection

Overweight/ObesityCondition

BGM0504 Injection multi-dose pen, BGM0504 Injection single-dose penTreatment

China1 locations

BrightGene Bio-Medical Technology Co., Ltd.Sponsor

Updated 2026-02-03 · NCT07382908See eligibility →

Recruiting nowPhase 3

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Adolescents With Obesity or Overweight With Weight-Related ComorbiditiesCondition

Placebo, IBI362Treatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-01-08 · NCT07255209See eligibility →

Recruiting nowNot applicable

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Adults With Simple ObesityCondition

Semaglutide, TirzepatideTreatment

China1 locations

Second Affiliated Hospital, Zhejiang University, School of MedicineSponsor

Updated 2025-12-19 · NCT07293325See eligibility →

Recruiting nowNot applicable

COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial

Hypoxia, Esophageal CancerCondition

the COMBO Endoscopy Oropharyngeal Airway Group, Regular Nasal CannulaTreatment

China3 locations

Zhejiang UniversitySponsor

Updated 2025-09-10 · NCT06796764See eligibility →

Recruiting nowNot applicable

The Jiaxing Birth Cohort in China

Childhood Obesity, AnemiaCondition

No interventionTreatment

China1 locations

Zhejiang UniversitySponsor

Updated 2018-01-23 · NCT03217656See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 2

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

Obesity, OverweightCondition

Mazdutide(Dual GLP-1R/GCGR Agonist), PlaceboTreatment

China6 locations

Tongji HospitalSponsor

Updated 2026-08-24 · NCT07781150See eligibility →

Opening soonNot applicable

Polygonatum Sibiricum Reduces Visceral Fat in Obese Adults

Visceral Obesity, Metabolic SyndromeCondition

Polygonatum sibiricum, Lifestyle InterventionTreatment

China1 locations

Zhejiang Provincial Tongde HospitalSponsor

Updated 2026-08-12 · NCT07759323See eligibility →

Opening soonNot applicable

Effects of Exercise Sequence and Meal Sequence on Weight Management Among Children and Adolescents With Overweight or Obesity: The STEP Trial

Obesity & Overweight, Insulin ResistanceCondition

Carbohydrate-last eating, Sequential trainingTreatment

China9 locations

Peking UniversitySponsor

Updated 2026-07-17 · NCT07712068See eligibility →

Opening soonNot applicable

The Resistant Starch Intervention for Cognitive Enhancement

Cognitive Impairment, Diet InterventionsCondition

High resistant starch staple foods, Regular starch staple foodsTreatment

China1 locations

Second Affiliated Hospital, Zhejiang University, School of MedicineSponsor

Updated 2025-09-03 · NCT07152483See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 2

A Study of CS060380 Tablets in Patients With MASH and Obesity

Metabolic Dysfunction-associated Steatohepatitis (MASH), ObesityCondition

semaglutide, CS060380Treatment

China12 locations

Cascade Pharmaceuticals, IncSponsor

Updated 2026-08-10 · NCT07466017See eligibility →

Active, not recruitingNot applicable

Energy Metabolism Profiles Over Weight-loss and Eating Responses

Homeostasis, Metabolism and Nutrition DisorderCondition

General lifestyle and nutritional education, Personalized nutritional and lifestyle weight reduction interventionTreatment

China1 locations

Chinese Academy of SciencesSponsor

Updated 2026-02-09 · NCT05785221See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Hangzhou, China

Current studies

Related cities